KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Cash & Equivalents (2016 - 2025)

Tenet Healthcare's Cash & Equivalents history spans 17 years, with the latest figure at $2.9 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 4.5% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, down 4.5%, while the annual FY2025 figure was $2.9 billion, 4.5% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.9 billion at Tenet Healthcare, down from $3.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $4.1 billion in Q3 2024 and bottomed at $766.0 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $2.2 billion (2021), against an average of $2.1 billion.
  • The largest annual shift saw Cash & Equivalents plummeted 63.71% in 2022 before it soared 288.43% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $2.4 billion in 2021, then tumbled by 63.71% to $858.0 million in 2022, then surged by 43.12% to $1.2 billion in 2023, then soared by 145.85% to $3.0 billion in 2024, then fell by 4.5% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for THC's Cash & Equivalents are $2.9 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.6 billion (Q2 2025).